Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551
- 82 Downloads
To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma concentrations with response and toxicity.
Eligible patients had relapsed Hodgkin lymphoma (HL) treated with one or two prior regimens, low grade non-Hodgkin’s lymphoma (NHL) treated with one or two prior regimens, or aggressive NHL treated with one prior regimen. The first nine patients received 9-AC dimethylacetamide 0.85 mg/m2 per day intravenously over 72 h every 2 weeks and the remaining 27 patients received 9-AC/colloidal dispersion 1.1 mg/m2 per day. Patients received a minimum of three cycles unless progression or intolerable toxicity occurred. Responding patients received two cycles past best response with a minimum of six cycles.
CALGB 9551 accrued 37 patients from April 1996 through October 2000; one patient with HD, 18 patients with indolent lymphoma, and 17 patients with aggressive lymphoma. The overall response rate was 17%, with response rates of 11% (2 partial responses) in patients with indolent histologies and 23% (1 complete response, 3 partial responses) in patients with aggressive histologies. The patient with HD did not respond. Response rates were similar for both drug formulations. The median remission duration for the six responders was 6.5 months, with one remission lasting longer than 12 months. Significant grade 3 and 4 toxicities included neutropenia (66%), anemia (31%), and thrombocytopenia (36%), with 20% of patients experiencing grade 3 or 4 infection. No treatment related deaths occurred. Steady state serum concentrations did not correlate with patient response or toxicity.
Single agent 9-AC has modest activity in aggressive non-Hodgkin’s lymphomas.
KeywordsRelapsed non-Hodgkin’s lymphoma 9-Aminocamptothecin (9-AC) Topoisomerase I inhibitor Pharmacokinetics
The research for CALGB 9551was supported, in part, by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman) and to the CALGB Statistical Center (Stephen George, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
- 2.Ota K, Ohna R, Shirakawa S et al (1994) Late Phase II study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematologic Malignancies. Japanese J Ca Chemoth 21(7):1047–1055 (Japanese)Google Scholar
- 3.Sarris AH, Romaguera J, Hagemeister FB et al (2001) Irinotecan in relapsed or refractory non-Hodgkins lymphoma. Oncology (Williston Park) 15(7 Suppl 8):53–56Google Scholar
- 10.Rubin E, Wood V, Bharti A et al (1995) A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Canc Res 1:269–276Google Scholar
- 12.Eder JP, Supko JG, Lynch T et al (1998) Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Canc Res 4(2):317–324Google Scholar